Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Crit Rev Microbiol. 2023 Aug;49(4):455-468. doi: 10.1080/1040841X.2022.2080526. Epub 2022 Aug 4.
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with a high mortality rate and a poor prognosis. The human microbiota has been confirmed to participate in oncogenesis and may influence the treatment response to both chemotherapy and immunotherapy. Evidence for the association of the microbiota with PDAC risk, tumorigenesis, treatment response, and survival period is rapidly emerging. The oral microbiota and gut microbiota have the potential to be used in early diagnosis and risk stratification. Intratumor microbiota-targeted intervention strategies may be used as adjuvants to current treatments to improve therapeutic efficacy and overall survival. Here, we summarize the effect and association of the oral, gut and intratumor microbiota on the oncogenesis, progression and treatment of PDAC, as well as the potential of the microbiota to serve as a biomarker for the diagnosis and prognosis of PDAC, as well as a therapeutic target.
胰腺导管腺癌（PDAC）是一种侵袭性疾病，死亡率高，预后差。人类微生物群已被证实参与肿瘤发生，并可能影响化疗和免疫治疗的治疗反应。微生物群与 PDAC 风险、肿瘤发生、治疗反应和生存时间之间关联的证据正在迅速出现。口腔微生物群和肠道微生物群有可能用于早期诊断和风险分层。肿瘤内微生物群靶向干预策略可作为当前治疗的辅助手段，以提高治疗效果和总生存率。在这里，我们总结了口腔、肠道和肿瘤内微生物群对 PDAC 的发生、发展和治疗的影响和关联，以及微生物群作为 PDAC 诊断和预后的生物标志物以及治疗靶点的潜力。
